# Endpoint selection in Huntington’s disease trials: how neuroimaging advances drive better outcomes 14 Apr 26 webinars # Endpoint selection in Huntington’s disease trials: how neuroimaging advances drive better outcomes [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/webinars/endpoint-selection-in-huntingtons-disease-clinical-trials-and-how-advances-in-neuroimaging-can-drive-better-trial-outcomes/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/webinars/endpoint-selection-in-huntingtons-disease-clinical-trials-and-how-advances-in-neuroimaging-can-drive-better-trial-outcomes/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/webinars/endpoint-selection-in-huntingtons-disease-clinical-trials-and-how-advances-in-neuroimaging-can-drive-better-trial-outcomes/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/webinars/endpoint-selection-in-huntingtons-disease-clinical-trials-and-how-advances-in-neuroimaging-can-drive-better-trial-outcomes/) [ Play Video ](https://youtube.com/watch?v=qzgn2JSpRs4 "Play Video") Designing effective clinical trials in Huntington’s disease (HD) remains a significant challenge. Particularly when it comes to selecting endpoints that are sensitive, reliable, and clinically meaningful. In a condition characterised by gradual progression and complex pathology, the ability to accurately measure change is critical. Poor endpoint selection can lead to inconclusive results, increased costs, and delays in development. In this webinar, IXICO brings together leading experts to explore how endpoint selection can be optimised in HD clinical trials, alongside the growing role of neuroimaging in improving trial design and outcomes. ### About the speakers and moderator [Jeffrey D. Long, PhD](https://linkedin.com/in/jeffrey-long-b5266889/?lipi=urn%3Ali%3Apage%3Ad_flagship3_feed%3BPEHjLDXMQrOQW4r5oCyffQ%3D%3D) - **Professor Department of Psychiatry and Biostatistics - University of Iowa** Dr. Long is Professor in the Departments of Psychiatry and Biostatistics at the University of Iowa, where his research focuses on Huntington's disease (HD). He serves as co-chair of the C-PATH HD Regulatory Science Consortium (HD-RSC) Modeling Working Group and is a member of both the HD-RSC Coordinating Committee and the HD-RSC Regulatory Science Forum. With over 16 years of experience analyzing data from large HD observational studies—including Enroll-HD, Predict-HD, and Track-HD—Dr. Long and his collaborators have developed several disease progression indices used for clinical trial enrichment. Among these is the Huntington's Disease Integrated Staging System, designed to facilitate the planning and conduct of new clinical trials. [Marina Papoutsi](https://www.linkedin.com/in/marina-papoutsi-8210b318a/), **Senior Biomarker Scientist - IXICO** Marina Papoutsi is a Senior Biomarker Scientist at IXICO. Prior to joining IXICO, she was a senior research fellow at the UCL Huntington’s disease centre working with Prof Sarah Tabrizi. Marina worked for 9 years as part of the neuroimaging team developing and validating neuroimaging biomarkers in HD. She is a member of the EHDN Imaging Working Group and a member of the HDYO research committee. At IXICO she is the TA lead for HD and is collaborating with KOLs to advance regulatory discussions relating to the use of imaging biomarkers in HD clinical trials. **Moderator:** [Robin Wolz](https://www.linkedin.com/in/robin-wolz-9806849/), **Chief Scientific Officer - IXICO** Robin Wolz has over 15 years of experience in the development of innovative analytics solutions in healthcare with a focus on imaging technology. Prior to IXICO, Robin held different roles at Philips in the Research and Diagnostic X-Ray divisions. Robin holds a PhD in medical imaging and computer science from Imperial College London, focused on early detection of Alzheimer's disease. He is the co-author of more than 100 publications and holds multiple patents in the field of medical imaging and AI data analytics. Join us to gain insights into key considerations in trial planning, including how to define, what to measure, as well as an overview of the latest advances in imaging analytics. **This webinar concluded April 22nd 2026** [ Back to Webinars ](/news-and-resources/webinars/) ### Recents ![Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/assets/blog-images/AD-Webinar-2026-1__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 1 Oct 26 webinars [Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/news-and-resources/webinars/where-vascular-disease-and-alzheimers-meet-shared-pathways-to-cognitive-decline/) [Understanding Imaging in Parkinson’s Disease Trials: From Eligibility to Efficacy](/news-and-resources/webinars/understanding-imaging-in-parkinsons-disease-trials-from-eligibility-to-efficacy/) [Alzheimer’s Landscapes: Comorbidities, Novel Targets, and Imaging Through the Neuroradiologist’s Lens](/news-and-resources/webinars/alzheimers-landscapes-comorbidities-novel-targets-and-imaging-through-the-neuroradiologists-lens/) [ Advancing AD Clinical Trials Through Blood-Based Biomarkers & Amyloid PET Webinar](/news-and-resources/webinars/advancing-ad-clinical-trials-through-blood-based-biomarkers-and-amyloid-pet-webinar/) [Parkinson's Disease: Unveiling the Promise of Neuromelanin Sensitive Imaging](/news-and-resources/webinars/parkinsons-disease-unveiling-the-promise-of-neuromelanin-sensitive-imaging/) ### Library [November 2026](/news-and-resources/webinars/archive/2026/11/) [October 2026](/news-and-resources/webinars/archive/2026/10/) [September 2026](/news-and-resources/webinars/archive/2026/09/) [July 2026](/news-and-resources/webinars/archive/2026/07/) [June 2026](/news-and-resources/webinars/archive/2026/06/) [May 2026](/news-and-resources/webinars/archive/2026/05/) [April 2026](/news-and-resources/webinars/archive/2026/04/) [March 2026](/news-and-resources/webinars/archive/2026/03/) [February 2026](/news-and-resources/webinars/archive/2026/02/) [January 2026](/news-and-resources/webinars/archive/2026/01/) [2025](/news-and-resources/webinars/archive/2025/) [2024](/news-and-resources/webinars/archive/2024/) [2023](/news-and-resources/webinars/archive/2023/) [2022](/news-and-resources/webinars/archive/2022/) [2021](/news-and-resources/webinars/archive/2021/) [2020](/news-and-resources/webinars/archive/2020/) [2019](/news-and-resources/webinars/archive/2019/)